Regeneron is a leading global biotechnology company using the power of science to bring new medicines to patients. While we applaud the intent of the legislation, overall, we believe that its overall impact is to disincentivise drug development for the EU market. We appreciate the proposals to streamline regulatory processes to expedite the availability of new medicines to EU citizens.
RPI
Regeneron Pharmaceuticals Inc.
Company · Ireland · EU Transparency Register 045767293922-02
2
positions filed
in the 665 files tracked
2
legislative files
of 665 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #734 by legislative files engaged, a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2024
in the register since
Declares membership of
- EUCOPE
- Regeneron is corporate member of the Transform Alliance, the European Haemophilia Consortium and the European Federat…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Tarrytown, United states
- EU office
- Dublin
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Regeneron in PolicySpeak: request access →
Work at Regeneron Pharmaceuticals Inc.? so we know who speaks for it.
Their record over time
Regeneron Pharmaceuticals Inc. filed 2 positions between 8 Nov 2023 and 3 Aug 2026, across 2 of the 665 legislative files tracked here.
2023 · 1 filed2026 · 1 filed
What they argued
Regeneron is a leading biotechnology company that develops medicines for people with serious diseases, and has substantial clinical trial and regulatory activity in the EU. The Biotech Act's CTR and SPC proposals address real barriers to that work, but impact depends on consistent implementation across Member States and alignment of the EHDS Regulation secondary use provisions with CTR/EMA Policy 0070.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Regeneron Pharmaceuticals Inc. next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 73.
Is this your organization?
Everything on this page comes from Regeneron Pharmaceuticals Inc.’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.